Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanoderm 4% in facial melasma
NCT02095990Phase 3Completed
- Sponsor
- mesoestetic Pharma Group
- Start
- Mar 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melasma comparing Hydroquinone Side with Placebo Side (2 arms). Primary endpoint: Melasma Area and Severity Index at 8 weeks. Started Mar 2014; status: completed.
02
Drugs
hydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on NCT02095990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095990.